Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

JOURNAL ARTICLE published 1 February 2013 in Journal of Clinical Oncology

Authors: Jesús F. San Miguel | Rudolf Schlag | Nuriet K. Khuageva | Meletios A. Dimopoulos | Ofer Shpilberg | Martin Kropff | Ivan Spicka | Maria Teresa Petrucci | Antonio Palumbo | Olga S. Samoilova | Anna Dmoszynska | Kudrat M. Abdulkadyrov | Michel Delforge | Bin Jiang | Maria-Victoria Mateos | Kenneth C. Anderson | Dixie-Lee Esseltine | Kevin Liu | William Deraedt | Andrew Cakana | Helgi van de Velde | Paul G. Richardson